Biomol Ther.
2015 Jan;23(1):12-18. 10.4062/biomolther.2014.102.
Keratinocytic Vascular Endothelial Growth Factor as a Novel Biomarker for Pathological Skin Condition
- Affiliations
-
- 1College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan 426-791, Republic of Korea. onbae@hanyang.ac.kr
- 2College of Pharmacy, Natural Products Research Institute, Seoul National University, Seoul 151-742, Republic of Korea.
- 3College of Pharmacy, Chung-Ang University, Seoul 156-756, Republic of Korea.
- 4College of Pharmacy, Yeungnam University, Gyeongsan, 712-749, Republic of Korea.
- KMID: 2380357
- DOI: http://doi.org/10.4062/biomolther.2014.102
Abstract
- Skin is an emerging target tissue in pharmaceutical and cosmetic science. Safety assessment for dermal toxicity is a critical step for development of topically applicable pharmaceutical agents and ingredients in cosmetics. Urgent needs exist to set up toxicity testing methods for dermal safety, and identification of novel biomarkers for pathological cutaneous alteration is highly required. Here we will discuss if vascular endothelial growth factor (VEGF) has a potential as a biomarker for dermal impairment. Experimental and clinical evidences for induction of keratinocytic VEGF under pathological conditions will be reviewed.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Expression of Vascular Endothelial Growth Factor : Clinical Implications in Cervical Neoplasia
- Serum vascular endothelial growth factor as a marker of asthma exacerbation
- Expression of Vascular Endothelial Growth Factor and Peritumoral Brain Edema in Intracranial Meningiomas
- Vascular Endothelial Growth Factor Expression in Human Trohoblast Cell Line
- Expression of Vascular Endothelial Growth Factor in Astrocytic Tumors: Correlation to Peritumoral Brain Edema and Microvasculature
